<DOC>
	<DOCNO>NCT01823978</DOCNO>
	<brief_summary>This Phase I , non-randomized , dose escalation study safety , biomarkers , preliminary efficacy dendritic cell vaccine , BPX-201 , plus activate agent , AP1903 , patient metastatic castrate resistant prostate cancer .</brief_summary>
	<brief_title>Safety Study BPX-201 Dendritic Cell Vaccine Plus AP1903 Metastatic Castrate Resistent Prostate Cancer</brief_title>
	<detailed_description>This Phase I study therapeutic vaccine , BPX-201 , plus activate agent , AP1903 , patient mCRPC . Patients screen within 8 week prior first vaccine administration ( 4 week prior leukapheresis ) . The trial design consist 3 cohort 6 patient , receive escalate dos BPX-201 10 million ( M ) , 20M 40M cell , respectively . Dose escalation occur accord 3+3 design . Patients receive administration BPX-201 every week 6 cycle ( 1 cycle equal 2 week ) . Approximately 1.6 mL BPX-201 administer 8 intradermal injection ( 200μL ) treatment visit . On day follow vaccination , single 40 mg dose activate agent , AP1903 , administer via intravenous ( IV ) infusion 2 hour .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Written inform consent 2 . 18 year age old 3 . Histologically confirm , metastatic prostate cancer ( positive bone scan and/or measurable disease CT scan and/or MRI abdomen pelvis ) . 4 . Progressive disease androgen deprivation , defined Prostate Cancer Working Group 2 and/or Response Evaluation Criteria Solid Tumors criteria 5 . Laboratory requirement : Absolute neutrophil count ( ANC ) ≥ 1500/μL Bilirubin &lt; 1.5 x ULN Hemoglobin &gt; 8 g/dL PSA &gt; 2 ng/mL Platelets &gt; 100,000/µL AST ALT &lt; 2.5 x ULN Creatinine clearance ≥ 60mL/min Testosterone &lt; 50 ng/dL 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 life expectancy &gt; 12 week 7 . Patients receive hormonal therapy , include dose megestrol acetate ( Megace ) , Proscar ( finasteride ) , herbal product know decrease PSA level ( e.g . Saw Palmetto , PCSPES ) , agents abiraterone , TAK700 , MDV3100 well systemic corticosteroid use , must discontinue agent least four week prior study treatment . Progressive disease define must document discontinuation hormonal therapy ( exception LHRH agonist ) . 8 . Prior radiation therapy must complete &gt; 4 week prior enrollment patient must recover toxicity . Prior radiopharmaceutical ( strontium , samarium ) must complete ≥ 8 week prior enrollment . 9 . Because unknown potential risk gamete and/or develop embryo investigational therapy , patient must agree use adequate contraception ( barrier method male ) duration study participation , three month discontinue therapy . 1 . Prior chemotherapy prostate cancer , exception neoadjuvant chemotherapy , potential effect chemotherapy immune system . 2 . Prior sipuleucelT treatment investigational immunotherapy . 3 . Prostate cancer pain require regularly schedule narcotic . 4 . Current treatment systemic steroid therapy ( inhaled/topical steroid acceptable ) . Systemic corticosteroid must discontinue least 4 week prior first treatment . 5 . Clinically active autoimmune disease . 6 . Diagnosis prostate cancer neuroendocrine differentiation 7 . Known presence central nervous system metastasis , pleural effusion ascites 8 . Medical psychiatric illness would , opinion investigator , preclude participation study ability patient provide informed consent . 9 . Cardiovascular disease meet one following : congestive heart failure ( New York Heart Association Class III IV ) , active angina pectoris , recent myocardial infarction ( within last 6 month ) . 10 . Concurrent prior malignancy except follow : Adequately treat basal squamous cell skin cancer Adequately treat stage I II cancer patient currently complete remission Any cancer patient diseasefree 5 year 11 . Known HIV history immunodeficiency disorder . 12 . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric medical ( e.g . infectious ) illness . 13 . Any underlying medical psychiatric condition , opinion investigator make administration BPX201 AP1903 hazardous obscure interpretation AEs , condition associate frequent diarrhea . 14 . Any nononcology vaccine therapy use prevention infectious disease 1 month BPX201</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>metastatic</keyword>
	<keyword>castration resistant prostate cancer</keyword>
	<keyword>Therapeutic Vaccine</keyword>
	<keyword>Dendritic cell</keyword>
	<keyword>BPX-201</keyword>
	<keyword>BPX201</keyword>
	<keyword>AP1903</keyword>
</DOC>